What is tesamorelin and how does it differ from direct growth hormone injections?

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates your pituitary gland to produce and release its own growth hormone naturally. Unlike direct HGH injections that introduce external hormone into your body, tesamorelin works with your body's existing feedback mechanisms. This means the pituitary maintains control over GH production, preventing the supraphysiological levels and potential suppression of natural production that can occur with exogenous GH. Tesamorelin preserves the natural pulsatile pattern of GH release, which is important for optimal physiological effects.

Is tesamorelin FDA-approved, and what is it approved for?

Yes, tesamorelin (brand name Egrifta) is FDA-approved. It received approval in 2010 specifically for reducing excess abdominal fat in HIV-infected patients with lipodystrophy—a condition where antiretroviral therapy causes abnormal fat redistribution, including increased visceral (belly) fat. This makes tesamorelin one of the few peptides in the GH secretagogue class with full FDA approval for therapeutic use, giving it extensive clinical safety and efficacy data from rigorous regulatory review.

Can tesamorelin help with fatty liver disease?

Research is actively investigating tesamorelin for non-alcoholic fatty liver disease (NAFLD). A recently completed Phase 2 clinical trial at Massachusetts General Hospital found that tesamorelin significantly reduced liver fat content compared to placebo over 12 months of treatment. The mechanism involves GH's effects on hepatic lipid metabolism, including enhanced fatty acid oxidation and reduced fat accumulation in the liver. While not yet FDA-approved for this indication, the results are promising for a condition that affects approximately 25% of the global population and currently has limited treatment options.

What are the common side effects of tesamorelin?

The most common side effects reported in clinical trials include injection site reactions (redness, itching, pain), joint pain (arthralgia), peripheral swelling (edema), muscle pain (myalgia), and tingling sensations (paresthesia). These are generally mild to moderate and often diminish over time. The joint-related symptoms and fluid retention are class effects of GH-related therapies. Importantly, unlike some GH treatments, tesamorelin did not significantly worsen glucose metabolism in clinical trials, though it is still contraindicated in active malignancy and pregnancy.

How does tesamorelin compare to sermorelin?

Both are GHRH analogs that stimulate natural GH release, but they differ in several ways. Tesamorelin contains all 44 amino acids of native GHRH with a stabilizing modification, while sermorelin is a truncated fragment containing only the first 29 amino acids. Tesamorelin has a longer half-life (26-38 minutes vs. 10-20 minutes for sermorelin) and, most importantly, tesamorelin has current FDA approval with extensive Phase 3 clinical data, while sermorelin's previous FDA approval for pediatric use was discontinued. Tesamorelin's regulatory status provides more clinical validation and safety data.

Does tesamorelin reduce all body fat or just visceral fat?

Tesamorelin preferentially reduces visceral (abdominal) fat rather than subcutaneous fat or limb fat. Clinical trials showed significant reductions in trunk fat and visceral adipose tissue measured by CT scan, but minimal changes in extremity fat. This selective action makes tesamorelin particularly useful for addressing central adiposity and the metabolic complications associated with visceral fat accumulation, such as insulin resistance and cardiovascular risk. The preservation of limb fat was actually a desired outcome in HIV lipodystrophy patients who already suffered from peripheral fat wasting.

Can tesamorelin improve cognitive function?

Research is exploring tesamorelin's potential cognitive benefits. The SMART trial (Somatotrophics, Memory, and Aging Research Trial) examined GHRH effects on cognition in older adults and those with mild cognitive impairment, showing improvements in memory and executive function. A separate Phase 2 trial specifically studied tesamorelin for cognitive impairment in HIV-infected persons. The rationale involves IGF-1's neuroprotective effects—IGF-1 crosses the blood-brain barrier and has been linked to neuroplasticity and brain health. While promising, cognitive applications remain investigational.

What happens when you stop taking tesamorelin?

Clinical trials demonstrated that the benefits of tesamorelin on visceral fat reduction reverse upon discontinuation. In extension studies, patients who were switched from tesamorelin to placebo experienced re-accumulation of visceral adipose tissue. This suggests that ongoing treatment is necessary to maintain the fat-reducing effects. The reversal occurs because tesamorelin doesn't fundamentally change fat cell biology—it provides ongoing lipolytic stimulation through GH release that ceases when treatment stops. This is consistent with how the body naturally regulates fat stores.

Homechevron_rightPeptideschevron_rightTesamorelin

Growth Hormone

scheduleHalf-life: 26-38 minutes

Tesamorelin

Tesamorelin Acetate (TH9507)

shopping_cart

starResearch Grade

Purchase Tesamorelin

Check Availabilityarrow_forward

Tesamorelin is a synthetic analog of human growth hormone-releasing hormone (GHRH) consisting of all 44 amino acids of native GHRH with a trans-3-hexenoic acid modification. Marketed under the brand name Egrifta®, tesamorelin is the only GHRH analog currently FDA-approved for therapeutic use—specifically for reducing excess abdominal fat in HIV-infected patients with lipodystrophy. Unlike direct growth hormone administration, tesamorelin stimulates the pituitary gland to produce and release endogenous GH, maintaining physiological feedback mechanisms. Beyond its approved indication, tesamorelin is being actively researched for applications in non-alcoholic fatty liver disease (NAFLD), cognitive function in aging, and metabolic health optimization.

verifiedRecommended Supplier

Purchase Research-Grade Tesamorelin

Sourced from Ascension Peptides. Verified ≥≥98% purity, third-party tested.Note: For laboratory research use only.

shopping_cartBuy Now

What is Tesamorelin?
Research Benefits
How Tesamorelin Works
Research Applications

References

What is Tesamorelin?

Research Benefits

check_circle

FDA-approved for reducing visceral adipose tissue

check_circle

Stimulates natural pulsatile growth hormone release

check_circle

Preserves hypothalamic-pituitary feedback regulation

check_circle

Improves trunk fat and waist circumference

check_circle

May reduce liver fat in NAFLD

check_circle

Potential cognitive benefits in aging populations

check_circle

Favorable lipid profile effects

check_circle

Does not significantly impair glucose metabolism